Photo credit : AACR
This year, Yemaachi Biotech was proud to participate in the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the world’s largest and most influential cancer research conferences. AACR brings together leading researchers, clinicians, pharmaceutical companies, biotechnology innovators, and policymakers from across the globe to share breakthroughs that are shaping the future of cancer prevention, diagnosis, and treatment.
The meeting featured participation from many of the world’s leading cancer research and life sciences organizations, including Roche, Illumina, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, and numerous academic and industry partners working at the forefront of precision medicine and multi-omics research.
A key highlight for Yemaachi was our CEO, Dr. Yaw Bediako, chairing the session “Precision for All: Harnessing Multi-omic Technologies to Eliminate Cancer Inequalities.” The session focused on how emerging genomic and multi-omic technologies can help address disparities in cancer outcomes and ensure that advances in precision medicine benefit all populations. Dr. Bediako shared insights from The African Cancer Atlas (TACA), Yemaachi’s flagship initiative to build one of the world’s most diverse clinico-genomic cancer datasets and expand African representation in global cancer research. The session also featured presentations by two of our collaborators: Dr. Ireshyn S. Govender of the Council for Scientific and Industrial Research (CSIR), South Africa, on a proteomics-centred approach to mapping the African cancer landscape, and Dr. Nyasha Chambwe of The Feinstein Institute for Medical Research, who discussed the use of integrative multi-omic approaches to better understand endometrial cancer disparities.
Drawing on evidence from African cancer genomics studies, Dr. Bediako highlighted the scientific importance of studying Africa’s unparalleled genetic diversity and the opportunities this presents for global drug discovery and precision oncology. As he often emphasizes, “Africa has more genetic diversity than any other part of the world,” making African genomic data essential not only for African patients but for advancing cancer research globally.
Throughout the conference, Yemaachi engaged with researchers, clinicians, pharmaceutical companies, technology providers, and potential collaborators who share our commitment to making cancer research more inclusive and representative. Conversations centered on the growing importance of diverse genomic datasets, the future of AI-enabled cancer research, and the role African-led science can play in driving the next generation of discoveries.
AACR 2026 reinforced a message that has long been central to Yemaachi’s mission: meaningful progress in precision oncology requires broader representation of global populations in research. The enthusiastic response to Dr. Bediako’s presentation and the growing interest in The African Cancer Atlas reflect increasing recognition that Africa’s scientific leadership and genomic diversity are critical to the future of precision oncology.
Looking back on AACR 2026, we are delighted about the conversations, connections, and opportunities that emerged from the meeting. We left San Diego proud that Yemaachi continues to earn its place on the world’s biggest stages, not as spectators, but as leaders helping to define the future of cancer research.
See coverage of this session here: Genome Web